RLMD - Relmada Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
40.66
+0.36 (+0.89%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close40.30
Open40.30
Bid40.21 x 1800
Ask40.55 x 800
Day's Range40.25 - 41.00
52 Week Range4.60 - 48.00
Volume225,857
Avg. Volume155,484
Market Cap578.055M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-2.21
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.00
  • Top Pharmaceutical Stocks for Q1 2020
    Investopedia

    Top Pharmaceutical Stocks for Q1 2020

    The pharmaceutical business is part of the larger healthcare sector. Pharmaceutical products may be generic, such as those used for common ailments like the flu and colds, or branded, patented drugs used for treating rare diseases including certain types of cancers. Among the best-known pharmaceutical companies are Eli Lilly & Co. (LLY) and Merck & Co. (MRK).

  • Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
    PR Newswire

    Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Maged Shenouda has been appointed the Company's new Chief Financial Officer (CFO). Mr. Shenouda, who has nearly 30 years of biotechnology and equity research experience, has also stepped down from the Company's Board of Directors in order to join the executive management team. Relmada's current CFO, Charles Ence, will assume a new role in the expanded financial team as the Company's Chief Accounting and Compliance Officer.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary ...

  • Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
    PR Newswire

    Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointments of life sciences industry veterans, Eric Schmidt, Ph.D., and John Glasspool, to the Company's Board of Directors, effective December 19, 2019. Dr. Schmidt is currently Chief Financial Officer of Allogene Therapeutics and previously was as a leading Wall Street biotechnology industry analyst for over 20 years. Mr. Glasspool is currently the Chief Executive Officer of Anthos Therapeutics and previously served in multiple senior leadership positions at Novartis and Baxalta.

  • GlobeNewswire

    Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock

    NEW YORK, Dec. 10, 2019 -- Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing.

  • Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswire

    Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the closing of its previously announced underwritten public offering of 3,833,334 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 500,000 additional shares of common stock, at a public offering price of $30.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and offering expenses, were approximately $115.0 million.

  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
    PR Newswire

    Relmada Therapeutics Announces Pricing of Public Offering of Common Stock

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions and other estimated expenses payable by Relmada, are expected to be $100,000,020. In addition, Relmada has granted the underwriters a 30-day option to purchase up to an additional 500,000 shares of Relmada's common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on December 6, 2019, subject to customary closing conditions.

  • Relmada Therapeutics Announces Proposed Public Offering of Common Stock
    PR Newswire

    Relmada Therapeutics Announces Proposed Public Offering of Common Stock

    Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

  • What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) Shareholder Register?

    The big shareholder groups in Relmada Therapeutics, Inc. (NASDAQ:RLMD) have power over the company. Institutions often...

  • Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
    PR Newswire

    Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

    NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Relmada Therapeutics Inc. (NASDAQ: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, announced today ...

  • Benzinga

    Relmada Shares Hit 4-Year High As Depression Drug Aces Midstage Trial

    New York-based Relmada released top-line data from a Phase 2 study that evaluated its REL-1017-202, chemically dextromethadone, in 25mg once a day and 50mg daily doses as an adjunctive treatment in patients with treatment-resistant depression, or TRD. The 62 subjects enrolled in the study had an average age of 49.2 years, an average Hamilton Depression Rating Scale score of 25.3 and an average Montgomery-Asberg Depression Rating Scale score of 34, reflecting severe depression.

  • Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
    PR Newswire

    Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

    Findings show that REL-1017 has rapid onset and sustained antidepressant efficacy with statistically significant differences compared to placebo on all efficacy measures NEW YORK , Oct. 15, 2019 /PRNewswire/ ...

  • Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
    PR Newswire

    Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

    NEW YORK , Oct. 14, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced ...

  • Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market

    Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf.

  • Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

    NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB:RLMDD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the Company's common stock has been approved for listing on The Nasdaq Capital Market. "The listing of our stock on The Nasdaq Capital Market represents a substantial milestone for our company," said Sergio Traversa, CEO of Relmada Therapeutics. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases.

  • Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
    PR Newswire

    Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

    NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that its Board of Directors has approved a 1-for-4 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace on September 30, 2019, whereupon the shares of common stock will begin trading on a split-adjusted basis. "This reverse stock split is an important step in Relmada's corporate development as the maintenance of a minimum closing bid price of $4.00 would fulfill the share price requirement for an uplisting to NASDAQ," stated Sergio Traversa, CEO of Relmada Therapeutics.

  • Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
    PR Newswire

    Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

    NEW YORK, July 29, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the last subject has completed dosing with REL-1017 (dextromethadone) in the company's  double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as an adjunctive treatment in patients affected by treatment-resistant depression. "We are very excited to have achieved this important milestone in the clinical development of REL-1017 for major depressive disorder," said Dr. Ottavio Vitolo, Relmada Head of R&D and CMO. Thus far, the blinded data confirms the favorable safety and tolerability profile of REL-1017 previously observed in the Phase 1 studies.

  • Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
    PR Newswire

    Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles

    NEW YORK, June 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it will present an overview of the company's business operations and progress in clinical research and product development at the LD Micro Invitational Conference on Wednesday, June 5, 2019 at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. The presentation by Sergio Traversa, CEO of Relmada Therapeutics, is scheduled to begin at 11:40 a.m. PT (2:40 p.m. Eastern Time). A live webcast of the presentation will be available through the Company's website at www.relmada.com.

  • Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
    PR Newswire

    Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting

    NEW YORK, May 31, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that a review of the company progress in the development of REL1017 (d-methadone, dextromethadone) for the treatment of depression and other CNS disorders was presented this week during the 2019 American Society of Clinical Psychopharmacology meeting in Scottsdale, AZ. The poster presentation entitled, "Development of the N-Methyl-D-Aspartate Receptor (NMDAR) Antagonist d-Methadone (REL 1017) for the Treatment of Depression and Other CNS Disorders", reported previously announced results from multiple pre-clinical studies comparing the effects of d-methadone and ketamine in different behavioral animal models used to assess antidepressant activity.  Results showed that d-methadone produced improvements similar to ketamine across a range of key tests, including Forced Swim Test, Female Urine Sniffing Test, Novelty Suppressed Feeding Test, and a Chronic Unpredictable Stress protocol.

  • Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
    PR Newswire

    Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results

    NEW YORK, April 16, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that results of its N-methyl-D-aspartate receptor (NMDAR) antagonist REL1017 (dextromethadone) single ascending dose and multiple ascending dose studies were accepted for publication in the peer reviewed  Journal of Clinical Psychopharmacology.  REL1017 is Relmada's lead product candidate currently in a Phase 2 study in individuals with major depressive disorder (MDD) who have not responded to traditional antidepressants.

  • Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
    PR Newswire

    Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations

    NEW YORK, April 3, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Gina DiGuglielmo has joined the company as vice president and head of clinical operations. Ms. DiGuglielmo previously served as clinical operations advisor of Relmada since June 2017.  In her new role, Ms. DiGuglielmo will lead and oversee the clinical operations for Relmada's lead product candidate dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist in development as a rapid acting treatment of depression and potentially other CNS indications and will contribute to the advancement of the company's portfolio in the clinical phases.